Health Canada-approved cancer drug lifileucel remains inaccessible to patients awaiting provincial funding decisions
A 37-year-old Ontario father with metastatic melanoma, Alex Shved, is unable to access TIL therapy (lifileucel) — a personalized cancer treatment approved by Health Canada in August 2024 — because it is still under review for public funding by provincial health systems. The article highlights the gap between federal drug approval and provincial funding decisions, which leaves patients in limbo and unable to access potentially life-saving treatments.
Key quotes
Alex Shved has been e-mailing Ontario politicians and filing appeals at the speed of a man who knows he doesn't have time to waste.
Despite Health Canada having approved a commercial version of TIL therapy called lifileucel last August, Mr. Shved can't get it.
Ontario parents hope son's death can change Canada's approach to novel cancer treatments.
From the article
A bespoke treatment for metastatic melanoma is unavailable to Canadians because it is still being reviewed for public funding
Continue reading on theglobeandmail.comYou might also wanna read

‘Don’t have the time to wait’: Ontario man fighting Stage 4 cancer seeking answers on out-of-country coverage denial
CityNews·5h ago

Ontario man fighting Stage 4 cancer seeking answers on out-of-country coverage denial
TownAndCountryToday·7h ago

Ontario man fighting Stage 4 cancer seeking answers on out-of-country coverage denial
TownAndCountryToday·7h ago

STAT+: 931 days. The drug approval scandal hiding in plain sight
STAT·4h ago
HHS seeks to ease testosterone therapy restrictions for older men, sparking debate among doctors
The Trump administration's HHS is requesting updates to prescribing information for testosterone replacement therapy (TRT), aiming to roll b
HHS seeks to ease testosterone therapy restrictions for older men, sparking debate among doctors
The Department of Health and Human Services (HHS) is requesting updates to prescribing information for testosterone replacement therapy (TRT

Comments
Sign in to join the conversation.
No comments yet. Be the first.